JP6608698B2 - Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト - Google Patents

Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト Download PDF

Info

Publication number
JP6608698B2
JP6608698B2 JP2015514525A JP2015514525A JP6608698B2 JP 6608698 B2 JP6608698 B2 JP 6608698B2 JP 2015514525 A JP2015514525 A JP 2015514525A JP 2015514525 A JP2015514525 A JP 2015514525A JP 6608698 B2 JP6608698 B2 JP 6608698B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
sequence
polypeptide
single variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015514525A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015525211A (ja
JP2015525211A5 (enExample
Inventor
オウス・ダンカー，ヴェルベック
ノルテ，フリードリッヒ
ストルトラー，カトリーン
レーレマンス，トーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Medical Center Hamburg-Eppendorf
Original Assignee
University Medical Center Hamburg-Eppendorf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Medical Center Hamburg-Eppendorf filed Critical University Medical Center Hamburg-Eppendorf
Publication of JP2015525211A publication Critical patent/JP2015525211A/ja
Publication of JP2015525211A5 publication Critical patent/JP2015525211A5/ja
Application granted granted Critical
Publication of JP6608698B2 publication Critical patent/JP6608698B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2015514525A 2012-06-01 2013-05-31 Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト Active JP6608698B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261654417P 2012-06-01 2012-06-01
US61/654,417 2012-06-01
PCT/EP2013/061257 WO2013178783A1 (en) 2012-06-01 2013-05-31 P2x7 receptor antagonists and agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018108470A Division JP6681433B2 (ja) 2012-06-01 2018-06-06 Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト

Publications (3)

Publication Number Publication Date
JP2015525211A JP2015525211A (ja) 2015-09-03
JP2015525211A5 JP2015525211A5 (enExample) 2016-07-21
JP6608698B2 true JP6608698B2 (ja) 2019-11-27

Family

ID=48579032

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015514525A Active JP6608698B2 (ja) 2012-06-01 2013-05-31 Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト
JP2018108470A Active JP6681433B2 (ja) 2012-06-01 2018-06-06 Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018108470A Active JP6681433B2 (ja) 2012-06-01 2018-06-06 Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト

Country Status (6)

Country Link
US (2) US9908935B2 (enExample)
EP (1) EP2855518A1 (enExample)
JP (2) JP6608698B2 (enExample)
CN (1) CN104507964B (enExample)
AU (2) AU2013269606B2 (enExample)
WO (1) WO2013178783A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2747644C (en) 2008-12-19 2023-01-24 Ablynx N.V. Method for generation of immunoglobulin sequences
JP6608698B2 (ja) 2012-06-01 2019-11-27 アブリンクス エン．ヴェー． Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト
WO2014182601A1 (en) * 2013-05-08 2014-11-13 Children's Medical Center Corporation A method of preventing and treating type 1 diabetes, allograft rejection and lung fibrosis (by targeting the atp/p2x7r axis)
LT3248986T (lt) 2014-05-16 2022-03-25 Ablynx Nv Imunoglobulino kintami domenai
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
CN107614528A (zh) * 2015-04-02 2018-01-19 生物权威（英国）有限公司 疼痛治疗
JP7403224B2 (ja) * 2015-11-12 2023-12-22 アブリンクス エン．ヴェー． 改良されたｐ２ｘ７受容体結合剤およびこれを含むポリペプチド
PL233352B1 (pl) * 2016-09-15 2019-10-31 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe białko fuzyjne
CN109321589A (zh) * 2018-10-15 2019-02-12 潍坊医学院 一种制备p2x7r免疫原的方法
CN110054691B (zh) * 2019-05-09 2021-09-07 潍坊医学院 一种抗人p2rx7单克隆抗体的杂交瘤细胞系
CA3152181A1 (en) * 2019-08-23 2021-03-04 Unm Rainforest Innovations Non-opioid compositions and therapies for pain management
WO2022114122A1 (ja) 2020-11-30 2022-06-02 旭化成ファーマ株式会社 神経障害性疼痛を緩和させるための医薬
US20240415974A1 (en) 2022-12-23 2024-12-19 Ablynx N.V. Protein-based conjugation carriers
IL322519A (en) 2023-02-17 2025-10-01 Ablynx Nv Polypeptides that bind to the neonatal fc receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344860B2 (en) * 2003-04-03 2008-03-18 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
US8124730B1 (en) * 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
CA2747644C (en) * 2008-12-19 2023-01-24 Ablynx N.V. Method for generation of immunoglobulin sequences
JP6608698B2 (ja) 2012-06-01 2019-11-27 アブリンクス エン．ヴェー． Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト

Also Published As

Publication number Publication date
CA2875234A1 (en) 2013-12-05
AU2018217239A1 (en) 2018-08-30
JP2018162269A (ja) 2018-10-18
EP2855518A1 (en) 2015-04-08
CN104507964A (zh) 2015-04-08
AU2013269606A1 (en) 2014-12-18
JP6681433B2 (ja) 2020-04-15
AU2018217239B2 (en) 2020-07-30
US10544216B2 (en) 2020-01-28
JP2015525211A (ja) 2015-09-03
US9908935B2 (en) 2018-03-06
US20180244769A1 (en) 2018-08-30
WO2013178783A1 (en) 2013-12-05
US20150133637A1 (en) 2015-05-14
AU2013269606B2 (en) 2018-05-17
CN104507964B (zh) 2020-05-15

Similar Documents

Publication Publication Date Title
JP6681433B2 (ja) Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト
JP7708741B2 (ja) Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防
JP7084870B2 (ja) Ｇｉｔｒアゴニスト
JP2021510535A (ja) Ｈｅｒ３抗原結合性分子
JP6181040B2 (ja) 二特異性抗ｃｘｃｒ７免疫グロブリン単一可変ドメイン
JP2013519364A (ja) アゴニストｄｒ５結合ポリペプチド
CN116829186A (zh) 多特异性抗体及其用途
US20210269542A1 (en) Anti-gitr antigen-binding proteins and methods of use thereof
JP7827737B2 (ja) Ｖｅｇｆａ結合分子
AU2016352695B2 (en) Improved P2X7 receptor binders and polypeptides comprising the same
CA3042727A1 (en) Anti-gitr antigen-binding proteins and methods of use thereof
TW202600594A (zh) 結合構築體(一)
CN118541395A (zh) 用her3抗原结合分子治疗和预防癌症
WO2022002006A1 (zh) Fab-HCAb结构的结合蛋白
WO2023186113A1 (zh) 靶向pd-l1和cd40的抗原结合蛋白及其制备和应用
CA2875234C (en) P2x7 receptor antagonists and agonists
RU2795625C2 (ru) Антигенсвязывающие белки против gitr и способы их применения
TW202602922A (zh) 結合構築體(二)
TW202602935A (zh) 抗原結合蛋白構築體及其用途

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150313

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20151111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170321

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170608

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170921

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180606

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180614

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20180810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190904

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191024

R150 Certificate of patent or registration of utility model

Ref document number: 6608698

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250